ISCC

In vitro

  1. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway
    Pu J, Sharma A, Liu T, Hou J, Schmidt-Wolf IG. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. Clin Transl Immunology. 2024 Mar 25;13(3):e1500. doi: 10.1002/cti2.1500. PMID: 38529413; PMCID: PMC10961996.

  2. Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors
    Vaseq R, Sharma A, Li Y, Schmidt-Wolf IGH. Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors. Int J Mol Sci. 2023 Mar 15;24(6):5626. doi: 10.3390/ijms24065626. PMID: 36982701; PMCID: PMC10054817.

  3. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
    Li Y, Sharma A, Wu X, Weiher H, Skowasch D, Essler M, Schmidt-Wolf IGH. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines. Front Oncol. 2022 May 11;12:713476. doi: 10.3389/fonc.2022.713476. PMID: 35646685; PMCID: PMC9130779.

  4. A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells
    Garofano F, Sharma A, Abken H, Gonzalez-Carmona MA, Schmidt-Wolf IGH. A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells. Int J Mol Sci. 2022 Mar 29;23(7):3783. doi: 10.3390/ijms23073783. PMID: 35409142; PMCID: PMC8998663.

  5. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside
    Li Y, Sharma A, Maciaczyk J, Schmidt-Wolf IGH. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside. Int J Mol Sci. 2022 Jan 24;23(3):1311. doi: 10.3390/ijms23031311. PMID: 35163235; PMCID: PMC8835986.

  6. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation
    Wu X, Sharma A, Oldenburg J, Weiher H, Essler M, Skowasch D, Schmidt-Wolf IGH. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation. Front Immunol. 2021 Oct 7;12:731767. doi: 10.3389/fimmu.2021.731767. PMID: 34691037; PMCID: PMC8529192.

  7. PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines
    Li Y, Sharma A, Bloemendal MWJR, Schmidt-Wolf R, Kornek M, Schmidt-Wolf IGH. PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines. Oncol Lett. 2021 Aug;22(2):613. doi: 10.3892/ol.2021.12874. Epub 2021 Jun 23. PMID: 34257721; PMCID: PMC8243082.

  8. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells
    Sadeghlar F, Vogt A, Mohr RU, Mahn R, van Beekum K, Kornek M, Weismüller TJ, Branchi V, Matthaei H, Toma M, Schmidt-Wolf IGH, Kalff JC, Strassburg CP, González-Carmona MA. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. Cancer Immunol Immunother. 2021 May;70(5):1451-1464. doi: 10.1007/s00262-020-02746-x. Epub 2020 Nov 12. PMID: 33180184; PMCID: PMC8053193.

  9. FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells
    Setiawan MF, Rudan O, Vogt A, Gonzalez-Carmona MA, Langhans B, Schmidt-Wolf R, Garofano F, Strassburg CP, Lasarte JJ, Casares N, Lozano T, Weiher H, Schmidt-Wolf IGH. FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells. Anticancer Res. 2019 Oct;39(10):5369-5374. doi: 10.21873/anticanres.13730. PMID: 31570431.

  10. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells
    Hillebrand RM, Vogt A, Strassburg CP, Gonzalez-Carmona MA, Schmidt-Wolf IGH. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells. Anticancer Res. 2019 Sep;39(9):4643-4652. doi: 10.21873/anticanres.13645. PMID: 31519562.

  11. Efficacy of cytokine-induced killer cells targeting CD40 and GITR
    Biederbick KD, Schmidt-Wolf IGH. Efficacy of cytokine-induced killer cells targeting CD40 and GITR. Oncol Lett. 2019 Feb;17(2):2425-2430. doi: 10.3892/ol.2018.9849. Epub 2018 Dec 18. PMID: 30675308; PMCID: PMC6341903.

  12. Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
    Esser L, Weiher H, Schmidt-Wolf I. Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma. Int J Mol Sci. 2016 Jul 1;17(7):1056. doi: 10.3390/ijms17071056. PMID: 27376285; PMCID: PMC4964432.

  13. Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myelomaBullok KF, Sippel C, Schmidt-Wolf IG. Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma. Hematol Oncol. 2016 Dec;34(4):208-216. doi: 10.1002/hon.2200. Epub 2015 Mar 18. PMID: 25784599.

  14. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies
    Schmeel FC, Schmeel LC, Gast SM, Schmidt-Wolf IG. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci. 2014 Aug 21;15(8):14632-48. doi: 10.3390/ijms150814632. PMID: 25196601; PMCID: PMC4159872.

  15. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells
    Jäkel CE, Schmidt-Wolf IG. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther. 2014 Jul;14(7):905-16. doi: 10.1517/14712598.2014.900537. Epub 2014 Mar 28. PMID: 24673175.

  16. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma
    Jäkel CE, Hauser S, Rogenhofer S, Müller SC, Brossart P, Schmidt-Wolf IG. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol. 2012;2012:473245. doi: 10.1155/2012/473245. Epub 2012 Nov 6. PMID: 23193418; PMCID: PMC3501961.

  17. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells
    Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol. 2012;2012:238924. doi: 10.1155/2012/238924. Epub 2012 Mar 19. PMID: 22481963; PMCID: PMC3310246.

  18. Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells
    Schöttker B, Schmidt-Wolf IG. Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells. Ger Med Sci. 2011;9:Doc18. doi: 10.3205/000141. Epub 2011 Aug 4. PMID: 21863132; PMCID: PMC3158648.

  19. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells
    Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, Huang K, Zhou DH. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res. 2010 Sep;30(9):3493-9. PMID: 20944128.

  20. Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids
    Ziske C, Etzrodt PE, Eliu AS, Gorschlüter M, Strehl J, Flieger D, Messmer D, Schmitz V, Gonzalez-Carmona MA, Sievers E, Brossart P, Sauerbruch T, Schmidt-Wolf IG. Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids. Pancreas. 2009 Oct;38(7):758-65. doi: 10.1097/MPA.0b013e3181ae5e1a. PMID: 19546834.

  21. Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells​​​​​​​
    Erhardt M, Schmidt-Wolf IG, Sievers E, Frank S, Strehl J, von Lilienfeld-Toal M, Gorschlüter M. Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells. Arch Immunol Ther Exp (Warsz). 2006 Nov-Dec;54(6):403-9. doi: 10.1007/s00005-006-0048-5. Epub 2006 Nov 21. PMID: 17122879.

  22. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells
    González-Carmona MA, Märten A, Hoffmann P, Schneider C, Sievers E, Schmidt-Wolf IG, Sauerbruch T, Caselmann WH. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int. 2006 Apr;26(3):369-79. doi: 10.1111/j.1478-3231.2005.01235.x. PMID: 16584401.

  23. Transfection of human monocyte-derived dendritic cells with CpG oligonucleotides​​​​​​​
    Erhardt M, Gorschlüter M, Sager J, Ziske C, Strehl J, Lilienfeld-Toal MV, Schmidt-Wolf IG. Transfection of human monocyte-derived dendritic cells with CpG oligonucleotides. Immunol Cell Biol. 2005 Jun;83(3):278-85. doi: 10.1111/j.1440-1711.2005.01328.x. PMID: 15877606.

  24. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer​​​​​​​
    Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Ther. 2004 Aug 25;2:12. doi: 10.1186/1479-0556-2-12. PMID: 15329148; PMCID: PMC516021.​​​​​​​

  25. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model
    Schmidt T, Ziske C, Märten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 2003 Dec 15;63(24):8962-7. PMID: 14695214.

  26. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma
    Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2003 Mar 20;14(5):483-94. doi: 10.1089/104303403321467243. PMID: 12691613.

  27. Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells
    Märten A, Greten T, Ziske C, Renoth S, Schöttker B, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, Schmidt-Wolf IH. Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells. Cancer Immunol Immunother. 2002 Mar;51(1):25-32. doi: 10.1007/s00262-001-0251-5. Epub 2001 Dec 21. PMID: 11845257; PMCID: PMC11032866.

  28. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations​​​​​​​
    Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, Schmidt-Wolf IG. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001 Nov-Dec;24(6):502-10. doi: 10.1097/00002371-200111000-00007. PMID: 11759073.

  29. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells​​​​​​​
    Märten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, Schmidt-Wolf IG. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica. 2001 Oct;86(10):1029-37. PMID: 11602408.

  30. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells
    Flieger D, Kufer P, Beier I, Sauerbruch T, Schmidt-Wolf IG. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells. Cancer Immunol Immunother. 2000 Oct;49(8):441-8. doi: 10.1007/s002620000130. PMID: 11043851; PMCID: PMC11036984.

  31. Expansion of CD3+CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy​​​​​​​
    Lefterova P, Schakowski F, Buttgereit P, Scheffold C, Huhn D, Schmidt-Wolf IG. Expansion of CD3+CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy. Haematologica. 2000 Oct;85(10):1108-9. PMID: 11025613.

  32. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation​​​​​​​
    Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine. 2000 Sep;12(9):1385-90. doi: 10.1006/cyto.2000.0733. PMID: 10975999.

  33. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein​​​​​​​
    Märten A, Schöttker B, Ziske C, Weineck S, Buttgereit P, Huhn D, Sauerbruch T, Schmidt-Wolf IG. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein. J Immunother. 2000 Jul-Aug;23(4):464-72. doi: 10.1097/00002371-200007000-00010. PMID: 10916756.

  34. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity​​​​​​​
    Lefterova P, Märten A, Buttgereit P, Weineck S, Scheffold C, Huhn D, Schmidt-Wolf IG. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity. J Immunother. 2000 May-Jun;23(3):304-10. doi: 10.1097/00002371-200005000-00003. PMID: 10838659.

  35. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12​​​​​​​
    Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf GD, Huhn D, Schmidt-Wolf IG. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother. 1998 Dec;47(4):221-6. doi: 10.1007/s002620050524. PMID: 9875675; PMCID: PMC11037372.

  36. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells​​​​​​​
    Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993 Dec;21(13):1673-9. PMID: 7694868.

  37. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation​​​​​​​
    Schmidt-Wolf IG, Aihara M, Negrin RS, Blume KG, Chao NJ. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. Transfusion. 1992 Jan;32(1):42-5. doi: 10.1046/j.1537-2995.1992.32192116431.x. PMID: 1731434.

  38. Lymphokine-activated killer cell activity after cryopreservation​​​​​​​
    Schmidt-Wolf IG, Aihara M, Negrin RS, Blume KG, Chao NJ. Lymphokine-activated killer cell activity after cryopreservation. J Immunol Methods. 1989 Dec 20;125(1-2):185-9. doi: 10.1016/0022-1759(89)90092-6. PMID: 2607152.​​​​​​​